Eloxx Pharmaceuticals, Inc. (ELOX) |
|
6.7262 -0.324 (-4.59%)
|
05-31 11:41 |
|
Open: |
6.98 |
Pre. Close: |
7.05 |
|
High:
|
6.98 |
Low:
|
6.55 |
|
Volume:
|
11,351 |
Market Cap:
|
15(M) |
|
|
|
Technical analysis |
as of: 2023-05-31 12:17:08 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 9.43 One year: 12.73 |
| Support: |
Support1: 3.5 Support2: 2.92 |
| Resistance: |
Resistance1: 8.07 Resistance2: 10.89 |
| Pivot: |
7.18  |
| Moving Average: |
MA(5): 7.26  MA(20): 6.84
MA(100): 4.93 MA(250): 7.23 |
| MACD: |
MACD(12,26): 0.4 Signal(9): 0.5 |
| Stochastic oscillator: |
%K(14,3): 47.2 %D(3): 51 |
| RSI: |
RSI(14): 48.8 |
| 52-week: |
High: 19.2 Low: 1.7 |
| Average Vol(K): |
3-Month: 508 (K) 10-Days: 445 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ELOX ] has closed above bottom band by 44.5%. Bollinger Bands are 141.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.68 - 7.73 |
7.73 - 7.78 |
|
Low:
|
6.69 - 6.73 |
6.73 - 6.78 |
|
Close:
|
6.96 - 7.04 |
7.04 - 7.13 |
|
Company Description |
|
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts. |
Headline News |
Wed, 24 May 2023
Eloxx Pharmaceuticals Plans To Take ELX-02 Into Pivotal Trial For Alport Syndrome - Yahoo Finance
Wed, 17 May 2023
Will Eloxx Pharmaceuticals Inc (ELOX) Beat the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver
Tue, 16 May 2023
U.S. Stock Tumble On The Open As U.S. Retail Sales Rise In Less ... - The Dales Report
Tue, 16 May 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace
Mon, 15 May 2023
TSLA, AI, RUM, ELOX, NU: Top 5 Trending Stocks - Eloxx Pharmaceuticals (NASDAQ:ELOX), Tesla (NASDAQ:TSLA) - Benzinga
Mon, 15 May 2023
Healthcare Stocks Making Moves Monday: ELOX, VXRT, IBRX, CRVS, GLMD, LRMR, IPA, IMPL - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
2 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0.6 (%) |
|
% Held by Institutions
|
43.9 (%) |
|
Shares Short
|
53 (K) |
|
Shares Short P.Month
|
49 (K) |
Stock Financials |
|
EPS
|
-14.04 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-4.93 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.48 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-1.37 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
